Previous 10 | Next 10 |
home / stock / bmy / bmy articles
Medicare Part D beneficiaries facing rising drug costs received welcome news as changes brought about by the 2022 Inflation Reduction Act cap their...
Thursday, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics Inc (NASDAQ:CYTK) acquisition, dealin...
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and affo...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
On Wednesday, Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten ...
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. The forthcoming year will provide the first...
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the ...
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Ph...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...